GlobeNewswireUnresolved
Arletta Pharma Solutions Receives FDA Response Supporting the Clinical Development Program of Lybrido™ for Female Sexual Interest/Arousal Disorder in the US
FDA endorses key elements of Arletta Pharma's Phase 2 study of Lybrido, a dual-action therapy for women with FSIAD/HSDD, and opens path to a single Phase 3